 | • レポートコード：360iR22DE002 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、251ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査報告書では、2021年に4,617.11百万ドルであった世界の臨床微生物市場規模が、2022年に5,084.45百万ドルになり、2027年まで年平均10.29%で成長して8,313.77百万ドルに達すると予測しています。本報告書では、臨床微生物の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（実験室機器、微生物分析装置、試薬）分析、由来別（血流感染症、消化器系疾患、歯周病、呼吸器系疾患、性感染症）分析、検体種類別（血液、体液、脳脊髄液、糞便、唾液）分析、エンドユーザー別（学術・研究機関、病院・介護事業者、感染症、実験室、患者自己検査）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報など、以下の項目を掲載しています。本書に記載されている企業情報としては、Abbott Laboratories、Agilent Technologies, Inc、Alere Inc.、Becton, Dickinson and Company、Bio-Rad Laboratories, Inc.、bioMérieux SA、BIOTECHNOLOGY SOLUTIONS TX, LLC、Bruker Corporation、Cepheid、Danaher Corporationなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の臨床微生物市場規模：製品別 - 実験室機器の市場規模 - 微生物分析装置の市場規模 - 試薬の市場規模 ・世界の臨床微生物市場規模：由来別 - 血流感染症由来微生物の市場規模 - 消化器系疾患由来微生物の市場規模 - 歯周病由来微生物の市場規模 - 呼吸器系疾患由来微生物の市場規模 - 性感染症由来微生物の市場規模 ・世界の臨床微生物市場規模：検体種類別 - 血液微生物の市場規模 - 体液微生物の市場規模 - 脳脊髄液微生物の市場規模 - 糞便微生物の市場規模 - 唾液微生物の市場規模 ・世界の臨床微生物市場規模：エンドユーザー別 - 学術・研究機関における市場規模 - 病院・介護事業者における市場規模 - 感染症における市場規模 - 実験室における市場規模 - 患者自己検査における市場規模 ・世界の臨床微生物市場規模：地域別 - 南北アメリカの臨床微生物市場規模 アメリカの臨床微生物市場規模 カナダの臨床微生物市場規模 ブラジルの臨床微生物市場規模 … - アジア太平洋の臨床微生物市場規模 日本の臨床微生物市場規模 中国の臨床微生物市場規模 インドの臨床微生物市場規模 韓国の臨床微生物市場規模 台湾の臨床微生物市場規模 … - ヨーロッパ/中東/アフリカの臨床微生物市場規模 イギリスの臨床微生物市場規模 ドイツの臨床微生物市場規模 フランスの臨床微生物市場規模 ロシアの臨床微生物市場規模 … - その他地域の臨床微生物市場規模 ・競争状況 ・企業情報 |
The Global Clinical Microbiology Market size was estimated at USD 4,617.11 million in 2021 and expected to reach USD 5,084.45 million in 2022, and is projected to grow at a CAGR 10.29% to reach USD 8,313.77 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Clinical Microbiology to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Laboratory Instruments, Microbiology Analyzers, and Reagents.
Based on Source, the market was studied across Bloodstream Infections, Gastrointestinal Diseases, Periodontal Diseases, Respiratory Diseases, Sexually Transmitted Diseases, and Urinary Tract Infections.
Based on Specimen Type, the market was studied across Blood, Body fluids, Cerebrospinal Spinal Fluid, Fecal, Saliva, Serum, Synovial Fluid:, and Urine.
Based on End User, the market was studied across Academic & Research Institutes, Hospitals & Care Providers, Infectious Diseases, Laboratories, and Patient Self-Testing.
Based on Application, the market was studied across Autoimmune Diseases, Cardiology, Diabetes, Drug Testing, HIV/Aids, Infectious Diseases, Nephrology, and Oncology.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Clinical Microbiology market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clinical Microbiology Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Clinical Microbiology Market, including Abbott Laboratories, Agilent Technologies, Inc, Alere Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMérieux SA, BIOTECHNOLOGY SOLUTIONS TX, LLC, Bruker Corporation, Cepheid, Danaher Corporation, Hardy Diagnostics, Hologic, Inc., Liofilchem S.r.l., Merck KGaA, Neogen Corporation, QIAGEN, Inc., Rapid Micro Biosystems, Inc., Roche Diagnostics Corporation, Shimadzu Corporation, TCS Biosciences Ltd., The 3M Company, and Thermo Fisher Scientific, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Clinical Microbiology Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Clinical Microbiology Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Clinical Microbiology Market?
4. What is the competitive strategic window for opportunities in the Global Clinical Microbiology Market?
5. What are the technology trends and regulatory frameworks in the Global Clinical Microbiology Market?
6. What is the market share of the leading vendors in the Global Clinical Microbiology Market?
7. What modes and strategic moves are considered suitable for entering the Global Clinical Microbiology Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Important role played by clinical microbiology in management and control of infectious diseases and the delivery of healthcare services
5.1.1.2. Advancement in disease diagnostic processes
5.1.1.3. Epidemic outbreak and Infectious diseases
5.1.1.4. Increased research funding and public-private Investments
5.1.2. Restraints
5.1.2.1. Unsupportive Regulatory Framework
5.1.2.2. Limited reimbursement policies for microbiology testing procedures
5.1.3. Opportunities
5.1.3.1. Academic and industry collaboration
5.1.3.2. Improving healthcare infrastructure across emerging countries
5.1.4. Challenges
5.1.4.1. Operational barriers related to the use of diagnostic tests
5.1.4.2. Bundle offering of microbiology testing products
5.2. Cumulative Impact of COVID-19
6. Clinical Microbiology Market, by Product
6.1. Introduction
6.2. Laboratory Instruments
6.3. Microbiology Analyzers
6.4. Reagents
7. Clinical Microbiology Market, by Source
7.1. Introduction
7.2. Bloodstream Infections
7.3. Gastrointestinal Diseases
7.4. Periodontal Diseases
7.5. Respiratory Diseases
7.6. Sexually Transmitted Diseases
7.7. Urinary Tract Infections
8. Clinical Microbiology Market, by Specimen Type
8.1. Introduction
8.2. Blood
8.3. Body fluids
8.4. Cerebrospinal Spinal Fluid
8.5. Fecal
8.6. Saliva
8.7. Serum
8.8. Synovial Fluid:
8.9. Urine
9. Clinical Microbiology Market, by End User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Hospitals & Care Providers
9.4. Infectious Diseases
9.5. Laboratories
9.6. Patient Self-Testing
10. Clinical Microbiology Market, by Application
10.1. Introduction
10.2. Autoimmune Diseases
10.3. Cardiology
10.4. Diabetes
10.5. Drug Testing
10.6. HIV/Aids
10.7. Infectious Diseases
10.8. Nephrology
10.9. Oncology
11. Americas Clinical Microbiology Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Clinical Microbiology Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Clinical Microbiology Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Agilent Technologies, Inc
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Alere Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Becton, Dickinson and Company
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Bio-Rad Laboratories, Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. bioMérieux SA
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. BIOTECHNOLOGY SOLUTIONS TX, LLC
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Bruker Corporation
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Cepheid
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Danaher Corporation
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Hardy Diagnostics
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Hologic, Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Liofilchem S.r.l.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Merck KGaA
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Neogen Corporation
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. QIAGEN, Inc.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Rapid Micro Biosystems, Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Roche Diagnostics Corporation
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Shimadzu Corporation
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. TCS Biosciences Ltd.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. The 3M Company
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
15.22. Thermo Fisher Scientific, Inc.
15.22.1. Business Overview
15.22.2. Key Executives
15.22.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing